

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : VENKATRAMAN, Subramanian S., et al)
Serial No 08/987,372) Group Art Unit: 1615
Filed December 9, 1997) Examiner: E. Webman
For PHARMACEUTICAL HYDROGEL)
FORMULATIONS AND ASSOCIATED)
DRUG DELIVERY DEVICES AND)
METHODS)



RECEIVED
JUN 17 1999
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an Information Disclosure Statement is required.
- ☐ The fee of \$ 240.00 as set forth in 37 C.F.R. § 1.17(p), as per 37 § 1.97(c), is also enclosed.
- ☒ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), a petition requesting consideration of the Information Disclosure Statement, and the petition fee of \$ 130.00 as set forth in 37 C.F.R. § 1.17(i) are also enclosed.
- ☐ Charge \$ to Deposit Account No. 01-1173 for the fee due.
- ☐ A check in the amount of \$ is enclosed for the fee due.
- ☒ The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 01-1173.

This paper is submitted in triplicate

Respectfully submitted,

Date: June 8, 1999

Owen J. Bates
Owen J. Bates, Registration no. 40,346

ALZA Corporation
950 Page Mill Road
PO Box 10950
Palo Alto, CA 94303-0802
(415) 496-8267

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on: June 9, 1999 (date).

ALZA CORPORATION

By:

Henrietta Votaw
Henrietta Votaw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
VENKATRAMAN, Subramanian S., et al.)
Serial No: 08/987,372) Group Art Unit: 1615
Filed: December 9, 1997) Examiner: E. Webman
For: PHARMACEUTICAL HYDROGEL)
FORMULATIONS AND ASSOCIATED)
DRUG DELIVERY DEVICES AND)
METHODS)

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith patents, publications and other information of which they are aware, which they believe an examiner may consider to be material to the patentability of the claims of this application, and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

While this Supplemental Information Disclosure Statement may contain "material" information pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is either "material" or "prior art" to the invention disclosed and claimed in the above-referenced application unless specifically designated as such. Applicants specifically reserve the right, where appropriate, to avoid or antedate any such reference by the appropriate arguments or showings under 37 C.F.R. § 1.131 and § 1.608, or any other appropriate means.

A completed PTO Form 1449 listing each reference which is not a U.S. Patent application is submitted herewith, and it respectfully requested that an Examiner initialed copy of the PTO Form 1449 be returned to the undersigned.

☒ A copy of each reference therein listed accompanies this Supplemental Information Disclosure Statement.

-OR-

☐ NO copies of the references therein listed accompany this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.98(d), as each was previously cited by or submitted to the Patent

Office in prior application Serial No. , filed , which this application relies upon for an earlier filing date under 35 U.S.C. § 120.

This Supplemental Information Disclosure Statement is not a representation that a search has been made or that no other information material to the patentability of this invention exists.

☐ This Supplemental Information Disclosure Statement is being filed within three months of the filing or entry of the national stage of this application, or before the mailing of a first Office Action on the merits, whichever is later. No fee is required under 37 C.F.R. § 1.97(b). However, in the event that more than 90 days from filing have elapsed and a first Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the fee required under 37 C.F.R. 1.17(p) to Deposit Account Number 01-1173.

☒ This Supplemental Information Disclosure Statement is being submitted *after* three months from the date of filing or entry of the national stage or this application, or *after* the mailing of a first Office Action, whichever is later, but *before* the mailing date of either a final Office Action or a Notice of Allowance.

☐ The Commissioner is hereby authorized to charge the fee required under 37 C.F.R. § 1.17(p) to Deposit Account 01-1173.

-OR-

☒ Certification as specified in 37 C.F.R. § 1.97(e) follows:

☒ *Each* item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application no more than three months prior to the filing of this statement.

☐ *No* item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

The Examiner is hereby requested to consider these references and other information and make them of record in the above-referenced application. Applicants respectfully submit that the claims of this application are patentable over the above-cited references and information. Examination and allowance of this application at an early date are requested.

Respectfully submitted,

Date: June , 1999

By: Owen J. Bates
Owen J. Bates, Reg. No. 40,346
Attorney for Applicants

ALZA Corporation
950 Page Mill Road
PO Box 10950
Palo Alto, CA 94303-0802
(650) 496-8267

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 9, 1999.

ALZA CORPORATION

BY: Henrietta Votaw
Henrietta Votaw

**SUPPLEMENTAL
INFORMATION DISCLOSURE
CITATION**

PTO-1449



ATTORNEY'S DOCKET NO.:

ARC 2630

APPLICATION NO.:

08/987,372

APPLICANT:

Venkatraman, Subramanian S., et al.

FILING DATE: 12/09/97

GROUP: 1615

US PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,664,857	05/87	Nambu	264	28	
	4,925,603	05/90	Nambu	264	28	
	5,260,066	11/93	Wood et al.	424	447	

FOREIGN DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	EP 0 516 026 A1	12/92	Takeda Chemical Industries	A61K	47/32	
	WO 98/08492	03/98	Novo Nordisk A/S	A61K	9/70	
	WO 98/26760	06/98	ALZA Corporation	A61K	9/00	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages Etc.)

EXAMINER:

DATE CONSIDERED:

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.